Compare Agnico Eagle Mines Ltd (AEM) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agnico Eagle Mines Ltd vs State Street SPDR S&P Biotech ETF — how do they compare? Agnico Eagle Mines Ltd trades at $185.6 (market cap $92.01B), while State Street SPDR S&P Biotech ETF trades at $159.27. The key difference: Agnico Eagle Mines Ltd pays a 0.99% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Agnico Eagle Mines Ltd nearer its low. Which is the better fit depends on your goals.
| AEM | XBI | |
|---|---|---|
Market Cap | $92.01B | — |
Sector | Basic Materials | Broad Market / Factor |
52-Week High | $252.19 | $164.28 |
52-Week Low | $130.23 | $86.92 |
Enterprise Value | $88.85B | — |
Dividend Yield | 0.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agnico Eagle Mines (AEM) trades at $185.82, up 2.96% on the day, reflecting strong momentum amid record gold prices and robust earnings. The stock exhibits a bullish technical setup with support near $180 and resistance at $186, while fundamentals are supported by a 37.5% net income margin and consistent earnings beats. Recent news highlights operational strength, with Q2 2026 EPS of $3.05 surpassing estimates and management projecting 20-30% production growth organically.
Outlook remains positive given analyst consensus and gold's uptrend, but rising unit costs and production challenges pose risks. With a $219.63 average price target implying 18% upside, AEM offers growth exposure to gold, though investors should monitor cost inflation and execution of expansion plans.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Agnico Eagle Mines Ltd
Agnico Eagle Mines is a gold miner operating mines in Canada, Mexico, and Finland. It also owns 50% of the Canadian Malartic mine. Agnico operated just one mine, LaRonde, as recently as 2008 before bringing its other mines on line in rapid succession in the following years. The company produced more than 1.7 million gold ounces in 2020. Agnico Eagle is focused on increasing gold production in lower-risk jurisdictions.
Read more on AEM →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
